title: A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC).
abstract: OBJECTIVE
  The effectiveness of cisplatinum and vinorelbine (PVn) as a salvage regimen in patients with metastatic breast cancer was reported in previous studies. This report is a pilot study assessing the antitumor efficacy and safety of this regimen as first line therapy for advanced breast cancer patients.
  
  
  METHODS
  Thirty-five patients were enrolled: 22 with metastatic breast carcinoma and 13 with locally advanced breast carcinoma (stage III). A total of 4 cycles of PVn were planned. After the 4th cycle, patients with metastatic breast cancer received vinorelbine biweekly until disease progression or for a total of 12 cycles, whereas those with locally advanced breast cancer who showed complete or partial response underwent curative surgery.
  
  
  RESULTS
  The overall response rate of our whole population was 74.29%. For the metastatic breast cancer group, the overall response rate was 64%, with a median survival of 19 months (range 2-36). For the locally advanced breast cancer group, the overall response rate was 92.3% with a median time to disease progression of 26 months (range 25-27). Toxicity was acceptable, and no treatment-related mortality was encountered.
  
  
  CONCLUSIONS
  PVn is effective as first line treatment of advanced breast cancer with overall response rate of 64% in metastatic breast cancer and 92.3% in locally advanced breast cancer, and acceptable toxicity.
authors.affiliation: Department of Internal Medicine, American University of Beirut, Beirut, Lebanon. as04@aub.edu.lb
authors.forename: Ali
authors.initials: A
authors.lastname: Shamseddine
authors.forename: Mohammed
authors.initials: M
authors.lastname: Khalifeh
authors.forename: Aref
authors.initials: A
authors.lastname: Chehal
authors.forename: Teddy
authors.initials: T
authors.lastname: Saliba
authors.forename: Yasser Abou
authors.initials: YA
authors.lastname: Mourad
authors.forename: Ali
authors.initials: A
authors.lastname: Taher
authors.forename: Rahif
authors.initials: R
authors.lastname: Jalloul
authors.forename: Nizar
authors.initials: N
authors.lastname: Bitar
authors.forename: Azzam
authors.initials: A
authors.lastname: Dandashi
authors.forename: Jaber
authors.initials: J
authors.lastname: Abbas
authors.forename: Fady B
authors.initials: FB
authors.lastname: Geara
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D044584:Carcinoma, Ductal / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000556:secondary; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D010865:Pilot Projects; D012878:Skin Neoplasms / Q000556:secondary; D015996:Survival Rate; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine